Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


California ephedrine

This article was originally published in The Tan Sheet

Executive Summary

Gov. Gray Davis (D) has until Sept. 30 to sign legislation requiring warning labels on ephedra-containing dietary supplements. The version of AB 2294 that passed the state Assembly and Senate floors is identical to an amended bill that passed the Senate Appropriations Committee Aug. 24 (1"The Tan Sheet" Aug. 28, p. 16). The American Herbal Products Association and its members, which include ephedra supplement marketers Starlight International and Twinlab, rescinded their opposition to the bill Aug. 28. The Council for Responsible Nutrition and the Consumer Healthcare Products Association also have dropped their objections to the bill

You may also be interested in...

California Ephedrine Bill Slated For Senate Consideration Aug. 28

California legislation requiring warning labels on ephedra-containing dietary supplements passed out of the Senate Appropriations Committee Aug. 24 and is expected to go to the state Senate floor the week of Aug. 28. Assembly Bill 2294 was introduced by Assemblywoman Susan Davis (D) Feb. 24.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts